PROM1 and cancer: To evaluate whether the presence of CTC subtypes after therapy is linked to the course of disease, ROC analyses were performed to identify a cutoff value for numbers of the different subpopulations (CD133+ CTCs, CD49f+ CD133+ CTCs and PD-L1+ CD49f+ CD133+ CTCs) that discriminates between patients with and without recurrent cancers.